GLP-1 receptor agonists, originally developed for type 2 diabetes, are now transforming care across multiple conditions—including obesity, cardiovascular disease, neurodegenerative disorders, and inflammatory diseases. These drugs not only lower blood sugar and support significant weight loss but also reduce cardiovascular events, improve kidney and liver health, and show promise in treating Alzheimer’s, Parkinson’s, and even addiction. While gastrointestinal side effects are common, the overall safety and wide-ranging benefits make them a cornerstone of modern medicine. Remarkably, some patients even report losing cravings for unhealthy foods—like their brain simply “forgot” it ever liked pizza.
Keep Reading
Add A Comment